drugset
drugset / Trial / NCT05276726

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

NCT05276726 ↗

Phase 1/2 Recruiting 104 enrolled Allist Pharmaceuticals, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.

Timeline

Start
2022-08-17
Primary completion
2026-02
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Glecirasib Small molecule — Oral

Indications

non-small cell lung carcinoma